Nirsevimab is effective for protecting infants against respiratory syncytial virus (RSV)-associated lower respiratory tract ...

Professor Margie Danchin addresses declining childhood vaccination rates and vaccine hesitancy through trust-building ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial ...

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

Parental trust in clinicians drove RSV vaccine uptake, while confusion and limited access to reliable information hindered ...

A pooled analysis of data for AstraZeneca and Sanofi's respiratory syncytial virus (RSV) antibody nirsevimab has concluded that the drug is almost 80% effective at preventing lower respiratory ...

Monoclonal antibodies (mAbs) have revolutionized medicine, providing innovative treatments for many diseases. For decades, ...

Vulnerable premature babies needing extra protection against RSV will receive a long-lasting single injection of nirsevimab, ...

At a meeting to present its vaccines pipeline to investors today, the French pharma is highlighting the potential of Beyfortus (nirsevimab) for the protection of infants in their first RSV season ...

Babies born very prematurely will be offered protection against respiratory syncytial virus (RSV) with a long-acting antibody medicine. Nirsevimab provides protection with just one injection, ...

Vermont has the second lowest state fatality rate in the US (148.5 per 100K; Hawaii 113.8/100K). Mississippi (466.2/100K) and Oklahoma (461.5/100K) have the highest rates. The US average is 308.2/100K ...